Baird Maintains Neutral on Iovance Biotherapeutics, Raises Price Target to $11
Benzinga Newsdesk 3 weeks ago
Analyst RatingsNewsPrice Target
Baird analyst Colleen Kusy maintains Iovance Biotherapeutics (NASDAQ:IOVA) with a Neutral and raises the price target from $6 to $11.
Baird analyst Colleen Kusy maintains Iovance Biotherapeutics (NASDAQ:IOVA) with a Neutral and raises the price target from $6 to $11.